Collectively, our findings shed light on the molecular mechanisms underlying IH-induced hepatosteatosis helping to understand better the NAFLD pathogenesis and identifying CD36 as a potential target for new pharmacological therapies to NAFLD patients. The gene discussed is CD36; the disease is metabolic dysfunction-associated steatotic liver disease.